Walleye Capital
LGND icon

Walleye Capital’s Ligand Pharmaceuticals LGND Stock Holding History

Walleye Capital’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$94.8K Buy
+300
New +$70.7K ﹤0.01% 3922
2025
Q1 		– Sell
-300
Closed -$32.1K – 4719
2024
Q4 		$32.1K Sell
300
-2,500
-89% -$283K ﹤0.01% 4438
2024
Q3 		$280K Buy
+2,800
New +$282K ﹤0.01% 3766
2024
Q1 		– Sell
-5,600
Closed -$400K – 5664
2023
Q4 		$400K Buy
+5,600
New +$330K ﹤0.01% 3117
2023
Q1 		– Sell
-200
Closed -$13.4K – 4175
2022
Q4 		$13.4K Sell
200
-441
-69% -$28.7K ﹤0.01% 2720
2022
Q3 		$34K Buy
+641
New +$37.7K ﹤0.01% 2661

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Walleye Capital's LGND Position: Q2 2026 in Review

Walleye Capital sold out of Ligand Pharmaceuticals (LGND) in Q2 2026, closing a stake of 10,333 shares — an estimated $2.43M sold.

Walleye Capital first reported a position in LGND in Q2 2022 and held it in 8 quarters. The position peaked at $2.06M in Q1 2026. 416 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

  • Walleye Capital reported no remaining Ligand Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Walleye Capital sold 10,333 Ligand Pharmaceuticals shares in Q2 2026, an estimated $2.43M.
  • Walleye Capital first reported a position in Ligand Pharmaceuticals in Q2 2022 and held it in 8 quarters.
  • Walleye Capital's Ligand Pharmaceuticals position peaked at $2.06M in Q1 2026.
  • 416 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.